deCODE genetics Announces Third Quarter 2007 Financi...(d targeting a key mechanism involv...)

targeting a key mechanism involved in the formation of thrombi in the

vasculature but that is not addressed by existing drugs. The company is

now planning a similar study to analyze the safety and pharmacodynamic

effect of DG041 in the presence and absence of clopidogrel (Plavix(TM))

alone, and well as clopidogrel and aspirin. The results of that study

will likewise be used to provide a detailed understanding of the

relevant biomarkers to be analyzed in a Phase IIb trial of DG041, in

vascular disease patients many of whom will be concomitantly receiving

other therapies.

-- Diagnostics: deCODE MI(TM). Following the launch earlier this year of

deCODE T2(TM) and deCODE AF(TM), the company in October launched its

third reference laboratory test for gauging individual risk of common

diseases. deCODE MI(TM) detects single-letter variations in the genome

(called SNPs) that the company has associated with increased risk of

myocardial infarction (MI), or heart attack. The SNPs are located on

chromosome 9 and were discovered by deCODE earlier this year. As

described in the journal Science in July, deCODE scientists found that

people who carry two copies of these variants are at double the risk of

suffering an early heart attack -- before the age of 50 in men and 60

in women -- than are those who do not carry them. Heart attack remains

the leading cause of death in the industrialized world and early-onset

events are particularly dangerous because they frequently take both

patients and doctors by surprise. The risk factor detected by deCODE

MI(TM) is independent of other risks such as cholesterol, obesity and

smoking, and therefore provides a means of identifying individuals who

may derive particular benefit from earlier and more aggressive

'/>"/>